CTIS2023-508755-39-00RecruitingPhase 1
The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients with High-Risk, Early-Stage Globo H-Positive Triple Negative Breast Cancer - OBI-822-011
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Obi Pharma Inc.
- Enrollment
- 668
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 65+ (—)
- Sex
- All
Inclusion Criteria
- •1. Male or female patient =18 years., 10. Eastern Cooperative Oncology Group (ECOG) performance status =1., 11. Females must be either of non-childbearing potential, i.e., surgically sterilized (have documented sterilization, bilateral oophorectomy /salpingectomy at least 3 months before the start of the trial and/or hysterectomy), or one year postmenopausal; or if of childbearing potential must have a negative pregnancy test (urine or serum) at screening., 12. Males and females of childbearing potential and their partners must be willing to use effective contraception during the entire study Treatment Phase and for at least 4 weeks (28 days) after the last dose of study treatment., 13. Adequate hematological, hepatic and renal function as defined below: - Absolute neutrophil count (ANC) =1,500/µL - Platelets =75,000/µL - Hemoglobin =8.5 g/dL - Serum creatinine =1.5 × upper limit of normal (ULN) or calculated Creatinine clearance =55 mL/min for patients with creatinine levels >1.5 ×institutional ULN (glomerular filtration rate can also be used in place of creatinine or creatinine clearance may be calculated per institutional standard) - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =3 × ULN - Alkaline phosphatase (ALP) =2.5 × ULN - Serum total bilirubin =1.5 × ULN (unless Gilbert's disease is documented)., 14. Consent to participate with a signed and dated Institutional Review Board /Independent Ethics Committee -approved patient informed consent for the study prior to beginning any specific study procedures., 15. Ability to understand and willingness to complete all protocol required procedures., 2. Documented radiographic and histopathologic confirmed primary localized invasive breast cancer., 3. Histologically documented TNBC (estrogen receptor-negative [ER-] / progesterone receptor-negative [PR-] / human epidermal growth factor 2-negatove [HER2-]) defined as ER-negative and PR-negative (=5% positive cells stain by IHC for both ER and PR), and negative HER2/neustatus, confirmed on tumor sample. HER2/neu-negative will be defined as one of the following criteria: - IHC 0 or 1+ - Single-probe average HER2 gene copy number of <6 signals/nucleus - (ISH concordance with FISH HER2/neu chromosome 17 (CEP17) non-amplified ratio of <2., 4. Globo H IHC H-score =15 from the residual primary site/or lymphnode (if primary site is not available) tumor obtained at the time ofdefinitive surgery or initial diagnosis (only if surgical tumor sample is not available). Globo H expression will be determined during prescreening by a central laboratory. Instructions for submission of slides/tumor tissue blocks are provided in the protocol and study Lab Manual., 5. No evidence of metastatic disease in chest, abdomen, and pelvis by CT or other adequate imaging during the Screening Phase. Imaging within 3 months prior to randomization is acceptable as baseline scan. Bone scans and imaging of the brain at screening is optional, and should be symptom directed., 6. High-risk patients with no evidence of disease after completing standard treatment and meeting ONE of the following criteria: - Neoadjuvant chemotherapy followed by definitive surgery: Residual invasive disease following neoadjuvant chemotherapy defined as: A contiguous focus of residual invasive cancer in the surgical breast specimen measuring =1 cm in diameter and/or with residual invasive cancer in at least one axillary node (micrometastases or macrometastases), as determined b
Exclusion Criteria
- •1. Local recurrence of or previous history of any ipsilateral or contralateral invasive breast cancer within 10 years prior to randomization [for synchronous tumors see Exclusion Criteria #3]., 10. Any known hypersensitivity to active/inactive ingredients in the study drug formulation or known severe allergy or anaphylaxis to fusion proteins., 11. Prior receipt of a glycoconjugate vaccine for cancer immunotherapy., 12. Known history or positive for human immunodeficiency virus (HIV) positive, unless on effective anti-retroviral therapy with undetectable viral load within 6 months of therapy (note: HIV testing is not required for study entry)., 13. Known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection prior to randomization. Patients who have completed curative therapy and have undetectable viral load for HCV are eligible. For patients with evidence of chronic HBV infection, the HBV viral load must be undetectable on suppressive therapy. (note: HBV/HCV testing is not required for study entry)., 14. Any condition, including significant diseases and/or laboratory abnormalities that would place the patient at unacceptable risk for study participation., 15. Currently pregnant or breastfeeding women., 16. Currently participating in or has participated in a breast cancer therapeutic clinical trial within 4 weeks (28 days) prior to randomization., 2. Definitive clinical or radiologic evidence of metastatic disease., 3. Synchronous bilateral breast cancer, unless both tumors are confirmed as TNBC., 4. Have received any anti-cancer vaccines., 5. Concomitant treatment with anticancer therapy other than adjuvant SOC therapy (capecitabine; immune checkpoint inhibitor), or other investigational therapy, if expected during the study., 6. A history of other malignancies (except appropriately treated melanoma in situ, non-melanoma skin carcinoma, carcinoma in situ of the uterine cervix, follicular or papillary thyroid cancer or other nonbreast malignancies with a similar outcome to those mentioned above) within 5 years prior to randomization., 7. Have any active autoimmune disease or disorder that requires Systemic immunosuppressive/immunomodulatory therapy. NOTE: Autoimmune diseases that are confined to the skin (e.g., psoriasis) that can be treated with topical steroids alone are allowed during the study., 8. Oral/parenteral corticosteroid treatment (>5 mg/day of prednisone /equivalent), within 2 weeks prior to randomization or anytime during the study. NOTE: inhaled steroids for treatment of asthma; and topical steroids are allowed., 9. Any known uncontrolled concurrent illness that would limit compliance with study requirements, including but not limited to ongoing or active infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric disorders, or substance abuse.
Investigators
Similar Trials
Recruiting
Not Applicable
The GLORIA Study: A Phase 3, Randomized, Open-Label Study of theAnti-Globo H Vaccine Adagloxad Simolenin (OBI822)/OBI-821 in the AdjuvantTreatment of Patients with HighRisk, Early-Stage Globo H-Positive TripleNegative Breast CancerKCT0005816ovotech Asia Korea668
Recruiting
Phase 3
The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI 822)/OBI 821 in the Adjuvant Treatment of Patients with High Risk, Early-Stage Globo H-Positive Triple Negative Breast CancerC50 Cancer de mamaPER-026-21OBI PHARMA, INC13
Recruiting
Phase 1
Phase 3 Study of Adagloxad Simolenin (OBI-822)/OBI-821 Treatment for Breast Cancer PatientsTriple Negative Breast CancerMedDRA version: 20.0Level: PTClassification code 10075566Term: Triple negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001438-16-PLOBI Pharma, Inc.668
Active, not recruiting
Phase 1
Study of efficacy and safety of the compound NGR-hTNF in patient with advanced malignant pleural mesotheliomapplicableEUCTR2009-016879-29-GBMOLMED400
Active, not recruiting
Phase 1
GR015: Randomized double-blind phase III study of NGR-hTNF plus best investigator s choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM) - NGR015Patients with advanced malignant pleural mesothelioma (MPM)previously treated with pemetrexedMedDRA version: 12.1Level: LLTClassification code 10035605Term: Pleural mesothelioma malignant advancedEUCTR2009-016879-29-ITMOLMED390